Insulins and oral hypoglycemic medications

Daniel E. Hale, Wieland Kiess

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The management of childhood diabetes is rapidly evolving, reflecting both the recognition of new types of diabetes in pediatrics and the availability of new insulins. Over the past two decades there have been increasing numbers of children affected by type 2 diabetes, maturity onset diabetes of youth (MODY), and medical diabetes secondary to medication usage (e.g. prednisone) or disease process (e.g., cystic fibrosis). These forms of diabetes require familiarity with medications other than insulin and an understanding of appropriate treatment strategies. Simultaneously, after years of little change, there has been the relatively rapid introduction of new insulins (e.g., lispro, aspart, glargine) and more sophisticated means of insulin delivery (e.g., pumps, pens, inhalers). Taken as a whole, these trends present a challenge to the pediatric diabetes specialist. In this article, the medications that are now frequently used in diabetes treatment are reviewed, including the indications for use, the usual dose, dose adjustment strategies, common side effects and anticipated outcomes. The diabetes literature on the new insulins and diabetes medications is reviewed, with an emphasis on the limited pediatric data. The goal is to familiarize the practicing pediatric diabetes specialist with these medications and their usage.

Original languageEnglish (US)
Pages (from-to)153-162
Number of pages10
JournalPediatric Endocrinology Reviews
Volume2
Issue numberSUPPL. 1
StatePublished - Nov 2004

Fingerprint

Insulins
Hypoglycemic Agents
Pediatrics
Type 2 Diabetes Mellitus
Insulin Lispro
Insulin
Social Adjustment
Nebulizers and Vaporizers
Prednisone
Cystic Fibrosis
Therapeutics
Recognition (Psychology)

Keywords

  • Acarbose
  • Glargine
  • Hyperglycemia
  • Hypoglycemia
  • Insulin
  • Insulin sensitizer
  • Lipoatrophy
  • Lipohypertrophy
  • Meglitinide
  • Metformin
  • Sulfonylurea
  • Thiazolidinedione
  • Type 1 diabetes mellitus (T1DM)
  • Type 2 diabetes mellitus (T2DM)
  • Uptake blocker

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Hale, D. E., & Kiess, W. (2004). Insulins and oral hypoglycemic medications. Pediatric Endocrinology Reviews, 2(SUPPL. 1), 153-162.

Insulins and oral hypoglycemic medications. / Hale, Daniel E.; Kiess, Wieland.

In: Pediatric Endocrinology Reviews, Vol. 2, No. SUPPL. 1, 11.2004, p. 153-162.

Research output: Contribution to journalArticle

Hale, DE & Kiess, W 2004, 'Insulins and oral hypoglycemic medications', Pediatric Endocrinology Reviews, vol. 2, no. SUPPL. 1, pp. 153-162.
Hale DE, Kiess W. Insulins and oral hypoglycemic medications. Pediatric Endocrinology Reviews. 2004 Nov;2(SUPPL. 1):153-162.
Hale, Daniel E. ; Kiess, Wieland. / Insulins and oral hypoglycemic medications. In: Pediatric Endocrinology Reviews. 2004 ; Vol. 2, No. SUPPL. 1. pp. 153-162.
@article{cea5455044ce4fb4a2c599ba490ad465,
title = "Insulins and oral hypoglycemic medications",
abstract = "The management of childhood diabetes is rapidly evolving, reflecting both the recognition of new types of diabetes in pediatrics and the availability of new insulins. Over the past two decades there have been increasing numbers of children affected by type 2 diabetes, maturity onset diabetes of youth (MODY), and medical diabetes secondary to medication usage (e.g. prednisone) or disease process (e.g., cystic fibrosis). These forms of diabetes require familiarity with medications other than insulin and an understanding of appropriate treatment strategies. Simultaneously, after years of little change, there has been the relatively rapid introduction of new insulins (e.g., lispro, aspart, glargine) and more sophisticated means of insulin delivery (e.g., pumps, pens, inhalers). Taken as a whole, these trends present a challenge to the pediatric diabetes specialist. In this article, the medications that are now frequently used in diabetes treatment are reviewed, including the indications for use, the usual dose, dose adjustment strategies, common side effects and anticipated outcomes. The diabetes literature on the new insulins and diabetes medications is reviewed, with an emphasis on the limited pediatric data. The goal is to familiarize the practicing pediatric diabetes specialist with these medications and their usage.",
keywords = "Acarbose, Glargine, Hyperglycemia, Hypoglycemia, Insulin, Insulin sensitizer, Lipoatrophy, Lipohypertrophy, Meglitinide, Metformin, Sulfonylurea, Thiazolidinedione, Type 1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM), Uptake blocker",
author = "Hale, {Daniel E.} and Wieland Kiess",
year = "2004",
month = "11",
language = "English (US)",
volume = "2",
pages = "153--162",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Insulins and oral hypoglycemic medications

AU - Hale, Daniel E.

AU - Kiess, Wieland

PY - 2004/11

Y1 - 2004/11

N2 - The management of childhood diabetes is rapidly evolving, reflecting both the recognition of new types of diabetes in pediatrics and the availability of new insulins. Over the past two decades there have been increasing numbers of children affected by type 2 diabetes, maturity onset diabetes of youth (MODY), and medical diabetes secondary to medication usage (e.g. prednisone) or disease process (e.g., cystic fibrosis). These forms of diabetes require familiarity with medications other than insulin and an understanding of appropriate treatment strategies. Simultaneously, after years of little change, there has been the relatively rapid introduction of new insulins (e.g., lispro, aspart, glargine) and more sophisticated means of insulin delivery (e.g., pumps, pens, inhalers). Taken as a whole, these trends present a challenge to the pediatric diabetes specialist. In this article, the medications that are now frequently used in diabetes treatment are reviewed, including the indications for use, the usual dose, dose adjustment strategies, common side effects and anticipated outcomes. The diabetes literature on the new insulins and diabetes medications is reviewed, with an emphasis on the limited pediatric data. The goal is to familiarize the practicing pediatric diabetes specialist with these medications and their usage.

AB - The management of childhood diabetes is rapidly evolving, reflecting both the recognition of new types of diabetes in pediatrics and the availability of new insulins. Over the past two decades there have been increasing numbers of children affected by type 2 diabetes, maturity onset diabetes of youth (MODY), and medical diabetes secondary to medication usage (e.g. prednisone) or disease process (e.g., cystic fibrosis). These forms of diabetes require familiarity with medications other than insulin and an understanding of appropriate treatment strategies. Simultaneously, after years of little change, there has been the relatively rapid introduction of new insulins (e.g., lispro, aspart, glargine) and more sophisticated means of insulin delivery (e.g., pumps, pens, inhalers). Taken as a whole, these trends present a challenge to the pediatric diabetes specialist. In this article, the medications that are now frequently used in diabetes treatment are reviewed, including the indications for use, the usual dose, dose adjustment strategies, common side effects and anticipated outcomes. The diabetes literature on the new insulins and diabetes medications is reviewed, with an emphasis on the limited pediatric data. The goal is to familiarize the practicing pediatric diabetes specialist with these medications and their usage.

KW - Acarbose

KW - Glargine

KW - Hyperglycemia

KW - Hypoglycemia

KW - Insulin

KW - Insulin sensitizer

KW - Lipoatrophy

KW - Lipohypertrophy

KW - Meglitinide

KW - Metformin

KW - Sulfonylurea

KW - Thiazolidinedione

KW - Type 1 diabetes mellitus (T1DM)

KW - Type 2 diabetes mellitus (T2DM)

KW - Uptake blocker

UR - http://www.scopus.com/inward/record.url?scp=12344316755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344316755&partnerID=8YFLogxK

M3 - Article

C2 - 16456494

AN - SCOPUS:12344316755

VL - 2

SP - 153

EP - 162

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - SUPPL. 1

ER -